Resumen Congreso ATTD 2024

Nota periodística a la Dra. Carolina Gomez Martin con los mensajes destacados y novedades del Congreso ATTD 2024.

Descargar

1. Martens T, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin. A randomized clinical trial. JAMA 2021;325(22):2262-2272.​ - Carlson AL, et al. Flash glucose monitoring in type 2 patients managed with basal insulin in USA. BMJ Open Diabetes Res Care 2022;10(1):e002590.​

2. Guerci B, et al. Important decrease in hospitalizations for acute diabetes events following Libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther 2023 Jan;25(1):20-30.​

3. Miller E, et al. Libre improves HbA1c in people receiving GLP-1 therapy for type 2 diabetes. ATTD Conference, March 6-9, 2024, Florence, Italy.​ - Wright E, et al. Initiating GLP-1 therapy in combination with Libre provides greater benefit compared to GLP-1 alone. ATTD Conference, March 6-9, 2024, Florence, Italy.​

4. Choe HG, et al. Effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring in patients with type 2 diabetes. Results from the randomized open-label PDF study. Diabetes Care 2022;45(10):2224-2230.